Authors
Loading...
Systematic review shows blinatumomab improves complete response rates in newly diagnosed B-cell acute lymphoblastic leukemia, highlighting its favorable safety profile.
Kakarala et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: